Safety and Activity Study of PSCA-Targeted CAR-T Cells (BPX-601) in Subjects With Selected Advanced Solid Tumors

Inclusion Criteria:

* Metastatic castration-resistant prostate cancer (mCRPC), with progressive disease per PCWG3 criteria during or following the direct prior line of therapy.
* Measurable disease per RECIST v1.1 at baseline; subjects with mCRPC with bone only metastases must have measurable PSA.
* Age ≥18 years.
* Life expectancy \> 12 weeks.
* ECOG 0-1
* Adequate organ function.

Exclusion Criteria:

* Prostate cancer with unstable bone lesions or symptomatic/untreated coagulopathy, or history of \> Grade 2 hematuria within the previous 6 months.
* Prior CAR T cell or other genetically-modified T cell therapy. Prior treatment with an immune-based therapy for the treatment of prostate cancer, including cancer vaccine therapies are allowable.
* Symptomatic, untreated, or actively progressing central nervous system metastases.
* Impaired cardiac function or clinically significant cardiac disease.
* Pregnant or breastfeeding.
* Participant requires chronic, systemic steroid therapy.
* Severe intercurrent infection.
* Known HIV positivity.